METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST Russian patent published in 2023 - IPC A61K39/395 A61P11/06 

FIELD: medicine.

SUBSTANCE: disclosed use of an antibody or an antigen-binding fragment thereof that specifically binds to the interleukin-4 receptor (IL-4R) for the treatment of a subject suffering from oral corticosteroid (OCS) dependent asthma, which includes administering to the subject a loading dose of the antibody or an antigen-binding fragment thereof; and administering to the subject one or more maintenance doses of the antibody or antigen-binding fragment thereof, wherein the maintenance doses are administered during a treatment phase comprising an induction phase, an oral corticosteroid (OCS) reduction phase, and an OCS maintenance phase, and wherein the antibody or antigen-binding fragment thereof comprises three sequences of complementarity determining regions (CDRs) of the heavy chain, including SEQ ID NO: 3, 4 and 5, respectively, and three light chain CDR sequences comprising SEQ ID NO: 6, 7 and 8, respectively (options).

EFFECT: effect of the group of inventions is the safety and efficacy of therapy that prevents exacerbations and impaired lung function, improves asthma symptoms and control, and also reduces or eliminates the need for oral glucocorticoids.

21 cl, 48 dwg, 14 tbl, 6 ex